New research suggests that GLP-1 weight-loss drugs may significantly reduce complications after heart attacks by improving blood flow to heart tissue.
Groundbreaking research indicates that a popular class of weight-loss drugs could play a crucial role in preventing life-threatening heart complications by reopening blocked blood vessels following heart attacks. The study, published this week in Nature Communications, was conducted by researchers from the University of Bristol and University College London.
The research identifies a biological signaling pathway involving the brain, gut, and heart, which may explain how GLP-1 drugs—medications that mimic the hormone glucagon-like peptide-1—help protect heart tissue from a condition known as “no-reflow.” This condition occurs when tiny blood vessels within the heart muscle remain constricted even after the main artery has been cleared during emergency treatment.
Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, highlighted the significance of the findings. “In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” she stated in a press release. “This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.” The lack of blood flow can increase the risk of heart failure and death within a year, but GLP-1 medications may offer a preventive solution.
The study reveals that when the GLP-1 hormone is released in the gut or administered as a medication, it sends signals to the brain. The brain, in turn, signals the heart to activate specific potassium channels in tiny cells known as pericytes. When these channels open, the pericytes relax, allowing small blood vessels, or capillaries, to widen and improve blood flow to the heart muscle.
Using animal models and cellular imaging, the researchers tracked how GLP-1 interacts with heart tissue. They discovered that when potassium channels were removed, the protective effects of the drugs on the heart were lost, confirming the channels’ critical role in this process.
The findings suggest that existing GLP-1 medications, which are already prescribed for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to minimize tissue damage.
However, the researchers acknowledged several limitations in their study, including its reliance on animal models. Clinical trials will be necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Moreover, while the study emphasizes the drug’s immediate benefits during a heart attack, it does not clarify whether long-term use of the medication provides any pre-existing level of protection.
This research was primarily funded by the British Heart Foundation, underscoring the potential implications for future heart attack treatments.
According to Fox News, the study opens new avenues for understanding how existing medications can be utilized to enhance heart health and reduce complications following cardiac events.